pAAV-GFP control vector product blog
Tags: Control Vector; pAAV-GFP; pAAV-GFP control vector;
The pAAV-GFP n/a (Catalog #MBS168881) is a Control Vector and is intended for research purposes only. The product is available for immediate purchase.To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given control vector. We\'ve tested the pAAV-GFP Control Vector with the following immunoassay(s):
Testing Data
Testing Data #2
Testing Data #3
Testing Data #4
• Use this control vector to co-transfect along with AAV packaging vectors to produce a recombinant AAV control.
Adeno-associated viruses (AAVs) are derived from defective parvoviruses, which depend on essential helper functions provided by other viruses, such as adenovirus and herpes virus, for efficient viral replication and propagation. AAV has no etiologic association with any known diseases and has been successfully used to establish efficient and long-term gene expression in vivo in a variety of tissues without significant cellular immune responses or toxicity.
AAV has a single-stranded DNA genome which consists of approximately 4.7 kb. All characterized AAV serotypes share three key features, including two copies of AAV terminal repeats (ITRs), one rep region and one cap region. The ITRs are capable of forming T-shape secondary structure and are the only cis elements that are required for AAV replication, packaging, integration, and rescue. The rep region encodes four overlapping proteins designated as Rep78, Rep68, Rep52, and Rep40, according to the apparent molecular mass of the protein. In addition to their well-defined roles in AAV replication, Rep proteins also regulate AAV packaging and site-specific integration. The cap region encodes three structural proteins, VP1, VP2, and VP3. These three proteins share the same reading frame (see Figure 1). MyBioSource\'s AAV Helper-Free System allows the production of infectious recombinant human adeno-associated virus (rAAV) virions without the use of a helper virus (Figure 2). In the AAV Helper-FreeSystem, most of the adenovirus gene products required for the production of infective AAV particles are supplied on the plasmid pHelper (i.e. E2A, E4, and VA RNA genes) that is co-transfected into cells with human AAV vector DNA. The remaining adenoviral gene product is supplied by the 293 host cells, which stably express the adenovirus E1 gene. By eliminating the requirement for live helper virus the AAV Helper-Free System provides a safer and more convenient gene delivery system. In the AAV Helper-Free System, the rep and cap genes have been removed from the viral vector that contains AAV-2 ITRs and are supplied in trans on the plasmid pAAV-RC. The removal of the AAV rep and cap gense allows for insertion of a gene of interest in the viral genome.
Recombinant adeno-associated viruses are important tools for gene delivery and expression. AAV has not been reported to cause any diseases. Together with its replication defective nature, AAV has good safety profile to be used in gene transfer in vivo, and as potential gene therapy vehicles. Recombinant AAV is capable of infecting a broad range of cell types including non-dividing cells and remaining asconcatemers for long-term expression. Compared with other viral vectors such as adenovirus, AAV elicits very mild immune response in animal models.